Skip to main content
release_alert
Welcome to the new Scholars 3.0! Read about new features and let us know what you think.
cancel

FGF21-FGFR4 signaling in cardiac myocytes promotes concentric cardiac hypertrophy in mouse models of diabetes.

Publication ,  Journal Article
Yanucil, C; Kentrup, D; Li, X; Grabner, A; Schramm, K; Martinez, EC; Li, J; Campos, I; Czaya, B; Heitman, K; Westbrook, D; Wende, AR; Faul, C ...
Published in: Scientific Reports
May 2022

Fibroblast growth factor (FGF) 21, a hormone that increases insulin sensitivity, has shown promise as a therapeutic agent to improve metabolic dysregulation. Here we report that FGF21 directly targets cardiac myocytes by binding β-klotho and FGF receptor (FGFR) 4. In combination with high glucose, FGF21 induces cardiac myocyte growth in width mediated by extracellular signal-regulated kinase 1/2 (ERK1/2) signaling. While short-term FGF21 elevation can be cardio-protective, we find that in type 2 diabetes (T2D) in mice, where serum FGF21 levels are elevated, FGFR4 activation induces concentric cardiac hypertrophy. As T2D patients are at risk for heart failure with preserved ejection fraction (HFpEF), we propose that induction of concentric hypertrophy by elevated FGF21-FGFR4 signaling may constitute a novel mechanism promoting T2D-associated HFpEF such that FGFR4 blockade might serve as a cardio-protective therapy in T2D. In addition, potential adverse cardiac effects of FGF21 mimetics currently in clinical trials should be investigated.

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Scientific Reports

DOI

EISSN

2045-2322

ISSN

2045-2322

Publication Date

May 2022

Volume

12

Issue

1

Start / End Page

7326

Related Subject Headings

  • Stroke Volume
  • Receptor, Fibroblast Growth Factor, Type 4
  • Myocytes, Cardiac
  • Mice
  • Humans
  • Heart Failure
  • Fibroblast Growth Factors
  • Disease Models, Animal
  • Diabetes Mellitus, Type 2
  • Cardiomegaly
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Yanucil, C., Kentrup, D., Li, X., Grabner, A., Schramm, K., Martinez, E. C., … Faul, C. (2022). FGF21-FGFR4 signaling in cardiac myocytes promotes concentric cardiac hypertrophy in mouse models of diabetes. Scientific Reports, 12(1), 7326. https://doi.org/10.1038/s41598-022-11033-x
Yanucil, Christopher, Dominik Kentrup, Xueyi Li, Alexander Grabner, Karla Schramm, Eliana C. Martinez, Jinliang Li, et al. “FGF21-FGFR4 signaling in cardiac myocytes promotes concentric cardiac hypertrophy in mouse models of diabetes.Scientific Reports 12, no. 1 (May 2022): 7326. https://doi.org/10.1038/s41598-022-11033-x.
Yanucil C, Kentrup D, Li X, Grabner A, Schramm K, Martinez EC, et al. FGF21-FGFR4 signaling in cardiac myocytes promotes concentric cardiac hypertrophy in mouse models of diabetes. Scientific Reports. 2022 May;12(1):7326.
Yanucil, Christopher, et al. “FGF21-FGFR4 signaling in cardiac myocytes promotes concentric cardiac hypertrophy in mouse models of diabetes.Scientific Reports, vol. 12, no. 1, May 2022, p. 7326. Epmc, doi:10.1038/s41598-022-11033-x.
Yanucil C, Kentrup D, Li X, Grabner A, Schramm K, Martinez EC, Li J, Campos I, Czaya B, Heitman K, Westbrook D, Wende AR, Sloan A, Roche JM, Fornoni A, Kapiloff MS, Faul C. FGF21-FGFR4 signaling in cardiac myocytes promotes concentric cardiac hypertrophy in mouse models of diabetes. Scientific Reports. 2022 May;12(1):7326.

Published In

Scientific Reports

DOI

EISSN

2045-2322

ISSN

2045-2322

Publication Date

May 2022

Volume

12

Issue

1

Start / End Page

7326

Related Subject Headings

  • Stroke Volume
  • Receptor, Fibroblast Growth Factor, Type 4
  • Myocytes, Cardiac
  • Mice
  • Humans
  • Heart Failure
  • Fibroblast Growth Factors
  • Disease Models, Animal
  • Diabetes Mellitus, Type 2
  • Cardiomegaly